A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia
- 12 April 2013
- journal article
- Published by Taylor & Francis Ltd in Journal of Medical Economics
- Vol. 16 (6), 720-735
- https://doi.org/10.3111/13696998.2013.782034
Abstract
Objective: The objective of this study was to provide up-to-date estimates of the clinical and economic burden that occurs during inpatient treatment of cancer patients with febrile neutropenia (FN). Methods: A retrospective cohort study was conducted using 2007–2010 hospital discharge data from the Premier database. The study population included adult patients with discharge diagnoses of neutropenia (ICD-9 code 288.0x) with fever or infection and receipt of intravenous antibiotics and female breast cancer, lung cancer, colorectal cancer, ovarian cancer, non-Hodgkin lymphoma (NHL), or Hodgkin lymphoma. Primary study outcomes were inpatient mortality, hospital length of stay (LOS), and total hospitalization cost for each patient’s first FN-related hospitalization. Logistic regressions (for mortality) and multivariate linear regressions (for LOS and cost) were conducted to assess the effect of comorbidities and infection types on study outcomes, adjusting for other patient and hospital characteristics. Results: Among 16,273 cancer patients hospitalized with FN, the inpatient case fatality rate was 10.6%, mean LOS was 8.6 days, and mean total hospitalization cost was $18,880. Lung cancer patients had the highest inpatient case fatality rate (15.7%), and NHL patients had the longest LOS (10.1 days) and the highest cost ($24,218). Multivariate analyses showed that most comorbidities were associated with a greater risk of mortality, longer LOS, and higher cost. Septicemia/bacteremia and pneumonia were associated with a greater risk of mortality, and most types of infection were associated with a longer LOS and higher cost. Limitations: The total burden of FN may be under-estimated in this study because outpatient treatment and any patient deaths or costs that occurred outside of Premier hospitals could not be captured. Conclusions: FN-related hospitalizations among cancer patients are costly and accompanied by considerable mortality risk. Substantial differences in the clinical and economic burden of FN exist depending on cancer types, comorbidities, and infection types.This publication has 27 references indexed in Scilit:
- Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databasesBMC Health Services Research, 2013
- Costs Associated with Febrile Neutropenia in the USPharmacoEconomics, 2012
- Trends in Neutropenia-Related Inpatient EventsJournal of Oncology Practice, 2012
- Costs of Home Versus Inpatient Treatment for Fever and Neutropenia: Analysis of a Multicenter Randomized TrialJournal of Clinical Oncology, 2011
- Febrile neutropenia: A critical review of the initial managementCritical Reviews in Oncology/Hematology, 2011
- Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective studyExperimental and Therapeutic Medicine, 2011
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEuropean Journal of Cancer, 2011
- 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice GuidelineJournal of Clinical Oncology, 2006
- Population-based Assessment of Hospitalizations for Neutropenia from Chemotherapy in Older Adults with Non-Hodgkin’s Lymphoma (United States)Cancer Causes & Control, 2006
- Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapyCancer, 2005